Lower response to trastuzumab emtansine in metastatic breast cancer patients with human epidermal growth factor receptor 2 immunohistochemistry score of 2 and fluorescence in situ hybridization positive compared with immunohistochemistry score of 3: a retrospective study
| Autor: | Teruo Yamauchi, Eriko Nakano, Jun Hashimoto, Shin Ogita, Shu Yazaki, Koyu Suzuki |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
0301 basic medicine Oncology Cancer Research medicine.medical_specialty Receptor ErbB-2 Breast Neoplasms Ado-Trastuzumab Emtansine 03 medical and health sciences chemistry.chemical_compound Antineoplastic Agents Immunological 0302 clinical medicine Breast cancer Trastuzumab Internal medicine medicine Humans Pharmacology (medical) Neoplasm Metastasis skin and connective tissue diseases neoplasms In Situ Hybridization Fluorescence Aged Retrospective Studies Aged 80 and over Pharmacology medicine.diagnostic_test business.industry Cancer Middle Aged medicine.disease Immunohistochemistry Metastatic breast cancer Progression-Free Survival 030104 developmental biology chemistry Trastuzumab emtansine 030220 oncology & carcinogenesis Female Pertuzumab business medicine.drug Fluorescence in situ hybridization |
| Zdroj: | Anti-Cancer Drugs. 31:973-978 |
| ISSN: | 0959-4973 |
| DOI: | 10.1097/cad.0000000000000939 |
| Popis: | Tumor human epidermal growth factor receptor 2 (HER2) status is defined by either protein expression using immunohistochemistry (IHC) or gene amplification using fluorescence in situ hybridization (FISH). Approximately 20% of HER2-positive breast cancer is HER2 IHC 2+/FISH-positive. Unlike trastuzumab, it has not been studied whether the response to trastuzumab emtansine (T-DM1) differs according to HER2-positive status. We retrospectively identified and reviewed medical records of all patients with HER2-positive advanced breast cancer (ABC) who received T-DM1 in our hospital from October 2013 to December 2016. We compared the objective response rate (ORR) and progression-free survival (PFS) between patients in the HER2 IHC 3+ group and those in the HER2 IHC 2+/FISH-positive group. A total of 39 patients (IHC 3+: n = 32; IHC 2+/FISH-positive: n = 7) were analyzed. Nineteen (48.7%), 13 (33.3%), and 29 (74.4%) patients had received at least one prior chemotherapy, more than three lines of chemotherapy, and prior pertuzumab for ABC, respectively. ORR was significantly higher in the IHC 3+ group than in the IHC 2+/FISH-positive group (53.3% vs. 0%, P = 0.024). Median PFS was 7.9 months in the IHC 3+ group versus 3.9 months in the IHC 2+/FISH-positive group (hazard ratio 0.68; 95% confidence interval 0.28-1.69, P = 0.408). Among the HER2-positive ABC patients treated with T-DM1, ORR was significantly worse in HER2 IHC 2+/FISH-positive than in HER2 IHC 3+ patients. Median PFS tended to be shorter in patients with HER2 IHC 2+/FISH-positive. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|